RPRX vs RVMD
Royalty Pharma plc and Revolution Medicines, Inc., both Healthcare
Revolution Medicines, Inc. is the larger company at $35B against $30B. Over the past year RVMD returned +517% against +71% for RPRX. Ryufin's sector-relative Smart Score puts RVMD ahead, 10/10 against 7/10.
| Figure | RPRX | RVMD |
|---|---|---|
| Last close | $61.80 | $216 |
| Market cap | $30B | $35B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | 32.9 | n/a |
| 1-year return | +71% | +517% |
| 5-year return | +87% | +635% |
| Ryufin Smart Scoresector-relative, 1–10 | 7/10 | 10/10 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
Royalty Pharma plc
Revenue of $674M in Q2 2026, net income $18M. Its largest reported line is Financial Royalty Assets, 94% of the disclosed total.
Revolution Medicines, Inc.
Open these two in the interactive comparison to add more names, change the period or read the correlation.